Xuyong Wei
Overview
Explore the profile of Xuyong Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yang X, Chen H, Shen W, Chen Y, Lin Z, Zhuo J, et al.
Nat Commun
. 2024 Oct;
15(1):8578.
PMID: 39362839
Fibroblast growth factor 21 (FGF21) is essential for modulating hepatic homeostasis, but the impact of FGF21 on liver graft injury remains uncertain. Here, we show that high FGF21 levels in...
12.
Wang S, Meng L, Xu N, Chen H, Xiao Z, Lu D, et al.
Cell Mol Immunol
. 2024 Sep;
21(11):1296-1308.
PMID: 39300319
Hepatocellular carcinoma (HCC) is a highly malignant tumor with significant global health implications. The role of CD4 T cells, particularly conventional CD4 T cells (Tconvs), in HCC progression remains unexplored....
13.
Yang M, Lin Z, Zhuang L, Pan L, Wang R, Chen H, et al.
MedComm (2020)
. 2024 Aug;
5(9):e678.
PMID: 39188937
Tumor recurrence is a life-threatening complication after liver transplantation (LT) for hepatocellular carcinoma (HCC). Precise recurrence risk stratification before transplantation is essential for the management of recipients. Here, we aimed...
14.
He C, Hu Z, Lin Z, Chen H, Cao C, Chen J, et al.
BMC Cancer
. 2024 Aug;
24(1):1042.
PMID: 39179959
Background: Chitinase-3 like-protein-1 (CHI3L1) is a member of the mammalian chitinase-like proteins and elevated serum CHI3L1 level has been proved to be associated with poor prognosis in hepatocellular carcinoma (HCC)....
15.
Xiang X, Wang K, Zhang H, Mou H, Shi Z, Tao Y, et al.
Cancer Immunol Res
. 2024 Aug;
12(11):1603-1620.
PMID: 39115356
The efficacy of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma (HCC) remains limited, highlighting the need for further investigation into the mechanisms underlying treatment resistance. Accumulating evidence indicates...
16.
Xu C, Su R, Lu Z, Song Y, Zhang X, Shu W, et al.
Genes Genomics
. 2024 Jul;
46(9):1045-1058.
PMID: 39078588
Background: The combination of Sorafenib and transcatheter arterial chemoembolization (TACE) exhibits limited efficacy in the treatment of certain advanced hepatocellular carcinomas (HCC), and the molecular mechanisms underlying resistance to this...
17.
Tang L, Xu S, Wei R, Fan G, Zhou J, Wei X, et al.
Mol Med
. 2024 Jul;
30(1):108.
PMID: 39060928
Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system, and the exact mechanism of HCC is still unclear. Transcription factor 7 like 2...
18.
ZIP4 inhibits Ephrin-B1 ubiquitination, activating Wnt5A/JNK/ZEB1 to promote liver cancer metastasis
Guo H, Su R, Lu X, Zhang H, Wei X, Xu X
Genes Dis
. 2024 Jul;
11(6):101312.
PMID: 39040931
No abstract available.
19.
Xu C, Fang X, Song Y, Xiang Z, Xu X, Wei X
Int J Biol Sci
. 2024 Jul;
20(9):3544-3556.
PMID: 38993564
Hepatic progenitor cells (HPCs) have a bidirectional potential to differentiate into hepatocytes and bile duct epithelial cells and constitute a second barrier to liver regeneration in the adult liver. They...
20.
He C, Shen W, Lin Z, Hu Z, Li H, Chen H, et al.
Transpl Immunol
. 2024 Jun;
85:102071.
PMID: 38866187
Background: To improve liver organ allocation, the model for end-stage liver disease (MELD) score was adopted in candidates reflecting the severity of liver disease and the physical condition of patients....